Fibromyalgia is a disorder of central pain processing characterised by widespread musculoskeletal pain, fatigue, and sleep disturbance, often accompanied by cognitive difficulties ('fibro fog').
Fibromyalgia is a disorder of central pain processing characterised by widespread musculoskeletal pain, fatigue, and sleep disturbance, often accompanied by cognitive difficulties ('fibro fog'). No primary tissue damage is evident; instead, dysregulation of pain-signal amplification in the spinal cord and brain—low serotonin, elevated substance P, sensitised pain receptors—perpetuates the syndrome. The condition predominantly affects women and is often triggered by trauma, infection, or stress. Cell therapy exploration in fibromyalgia is nascent; placental MSCs and their secreted exosomes are being investigated for immunomodulatory properties (shifting immune response away from pro-inflammatory cytokine production) and for potential neuromodulation through delivery of anti-inflammatory molecules to the central nervous system. The hypothesis is that systemic cellular or exosome infusion might dampen the amplified pain state and restore normal sleep and mood regulation.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €5,000–€25,000 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Exosomes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 1 |
For the clinic's own description, see our partner clinic Stem Plus.
Only 1 completed trial and 0 actively recruiting trials are registered specifically for fibromyalgia cell therapy, reflecting the early, exploratory stage of this application. That single published study involved placental MSC infusion in a small cohort (n≈20–30) and reported modest improvements in pain scores (average 20–30% reduction on visual analogue pain scale) and some improvement in fatigue severity. Biochemical markers of inflammation (IL-6, TNF-α) showed trending reductions. No control arm was present, and long-term follow-up was not reported.
Depending on assessment, a Fibromyalgia & Chronic Fatigue protocol may draw on:
Clinical applications of cell therapy for fibromyalgia are highly experimental and available in only a handful of private centres. Costs, where quoted, typically range from €4,000 to €7,000 for intravenous MSC infusion, though supportive testing (blood panels assessing cytokine profiles, baseline pain and fatigue questionnaires) may add €500–1,000. Insurance is not applicable because no standard treatment pathway exists; patients seeking this therapy are self-funding exploratory care.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Fibromyalgia & Chronic Fatigue cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Fibromyalgia & Chronic Fatigue.
Full Fibromyalgia & Chronic Fatigue FAQ → · Fibromyalgia & Chronic Fatigue cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача